The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Most Cited Paper
in DNA Repair Mechanisms
18 Months Post-Publication
Class of 2026
“The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/dna-repair-mechanisms/2026/
Topics
saruparib (AZD5305) · PARP inhibitor · olaparib · BRCA1/BRCA2 pathogenic alterations · PALB2 · Homologous recombination deficiency · Patient-derived xenograft models · reversion mutations · hypomorphic BRCA1 · RAD51 foci formation · Replication stress · Genomic instability · ceralasertib · ATR inhibitor · carboplatin combination · PARP inhibitor resistance · preclinical complete response rate · synthetic lethality
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited DNA Repair Mechanisms Papers, Class of 2026. https://pri.pepkio.com/top-papers/dna-repair-mechanisms/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459